India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Subscribe To Our Newsletter & Stay Updated
